Phase I trial of diaziquone (AZQ) plus GM-CSF

Lynn C. Hartmann, Matthew M. Ames, Joel M. Reid, Ronald L. Richardson

Research output: Contribution to journalArticle

Abstract

Diaziquone (AZQ) is a lipid soluble alkylating agent which was designed for increased CNS penetration. Its principle toxicity is myelosuppression. We conducted a phase I trial using AZQ in combination with GM-CSF to determine if the maximal tolerated dose (MTD) of AZQ could be escalated. Using GM-CSF on a standard schedule, we were unable to escalate the previously determined MTD of diaziquone with the use of this colony stimulating factor.

Original languageEnglish (US)
Pages (from-to)175-176
Number of pages2
JournalInvestigational New Drugs
Volume13
Issue number2
DOIs
StatePublished - Jun 1 1995

Keywords

  • AZQ
  • GM-CSF
  • diaziquone

ASJC Scopus subject areas

  • Oncology
  • Pharmacology
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Phase I trial of diaziquone (AZQ) plus GM-CSF'. Together they form a unique fingerprint.

  • Cite this

    Hartmann, L. C., Ames, M. M., Reid, J. M., & Richardson, R. L. (1995). Phase I trial of diaziquone (AZQ) plus GM-CSF. Investigational New Drugs, 13(2), 175-176. https://doi.org/10.1007/BF00872869